Genomic sequencing Assessment of 733 HER2-amplified Major and metastatic breast tumours unveiled sizeable enrichment of mutations that activate RAS–MAPK signalling in Highly developed tumours treated with prior anti-HER2 therapies121. These mutations, like NF1 and HER2 activating mutations, lead to resistance to tucatinib and neratinib. Paget’s disease on the breast: This https://www.directivepublications.org/journal-of-clinical-breast-cancer/